Medexus Pharmaceuticals Inc. (TSE:MDP – Get Free Report) has earned a consensus rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Separately, Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Get Medexus Pharmaceuticals alerts:Get Our Latest Stock Report on Medexus PharmaceuticalsMedexus Pharmaceuticals Price PerformanceMedexus Pharmaceuticals Company ProfileTSE MDP opened at C$2.86 on Thursday. Medexus Pharmaceuticals has a 1 year low of C$1.71 and a 1 year high of C$5.56. Read MoreReceive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.